Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
The articles confirm the model is finalized and moving into active implementation, but they introduce two specific new facts that materially enrich the strategic picture: (1) CMS has released a participant list (AHA article [10]), confirming the model is fully finalized and participation is identifiable — a signal that competitive benchmarking is now possible; and (2) hospitals are actively standing up task forces and vendors are launching CJR-X-specific products (articles [5], [8], [9]), which is implementation-phase evidence the existing analysis anticipated but could not confirm. The existing analysis's strategic logic, financial mechanics, and risk framing remain accurate. The new articles are largely confirmatory and operational, not analytically disruptive.
However, two additions are warranted: (a) the participant list release deserves explicit mention as a competitive intelligence opportunity, and (b) the emerging vendor ecosystem and task force activity provide evidence that the 14-month runway warning is now being acted upon — which slightly strengthens the urgency framing. The title header also needs correction: CJR-X is finalized (not "Proposed") based on articles [6], [7], and [10].
Mandatory Nationwide Bundled Payment for LEJR — Begins January 1, 2028
CJR-X is not an experiment. It is a nationwide mandate codified through the FY 2027 IPPS Final Rule under Section 1115A(c) expansion authority — meaning CMS bypassed the typical CMMI pilot-to-scale pathway and went directly to rulemaking. That procedural choice has teeth: any future modifications also require notice-and-comment rulemaking, insulating the model from administrative reversal by a future CMS administrator. Under the current Trump administration, with CMMI Director Abe Sutton overseeing the model, this structural durability is notable — CJR-X was locked in before any potential policy pivot could intervene.
The model's design reflects two deliberate bets. First, CMS is betting that the original CJR's $112.7 million in net savings (PY6-7, 2021-2023) was structural, not behavioral — meaning the discount mechanism alone will generate savings even if provider behavior doesn't change. OACT confirms this: target pricing alone produces 0.6% net savings before behavioral effects, driven by an effective average discount of approximately 1.3% (blended across the quality category distribution: 20% of hospitals at 2%, 30% at 2%, 30% at 1%, 20% at 0%).
Second, CMS is betting that the two-track architecture — CJR-X at 90 days for LEJR nationally, TEAM at 30 days for five surgical categories in selected hospitals — will generate comparative evidence on episode length. This isn't incidental. TEAM and CJR-X are explicitly designed to run in parallel, with TEAM hospitals excluded from CJR-X, creating a natural quasi-experiment. The policy implication: whichever model produces better net savings with equivalent quality will likely become the template for the next wave of mandatory bundled payment expansion.
The 29-variable risk adjustment framework (versus CJR's 3 adjusters) addresses the original model's most significant operational complaint — penalizing high-acuity and safety-net hospitals for case mix they don't control. The 29 adjusters include HCC count, 21 specific HCCs, prior PAC use, dual eligibility, disability status, and procedure type. At the hospital level, CMS risk adjusts for bed count and dual eligibility concentration. This is a material improvement, but hospitals with high proportions of MS-DRG 469 (MCC) cases should validate their risk adjustment coefficients immediately when preliminary target prices are released — the 3% retrospective trend cap creates asymmetric exposure if baseline spending is poorly modeled.
The 5% stop-loss for rural, Medicare-dependent, small rural, sole community, and high-dual hospitals (versus 20% for all others) is a meaningful protection but creates a hidden incentive problem: hospitals near that stop-loss threshold have diminished marginal incentive to reduce episode costs in the final months of a performance year. Finance teams should model whether their expected episode spending trajectory approaches the 5% or 20% floor before year-end.
The model's example reconciliation calculation provides a concrete anchor. With a $100,000 benchmark episode, a 1.0% final discount (Good CQS), retrospective trend of 1.060, and actual episode spending of $90,000, the reconciliation payment is $5,863. That represents a 5.9% margin on the episode — achievable, but only for hospitals that have already reduced post-acute utilization meaningfully below their regional benchmark.
Low-volume threshold: Hospitals with fewer than 31 LEJR episodes during the applicable 3-year baseline period are excluded from reconciliation. For most community hospitals, 31 episodes over 3 years (~10/year) is a low bar — most IPPS hospitals performing LEJRs will clear this easily. However, rural hospitals approaching this threshold should evaluate whether selective referral of complex cases to tertiary centers could inadvertently push them below the threshold, triggering exclusion.
Break-even framing: The 2% discount (applied to hospitals with Acceptable or Below Acceptable CQS) on a $100,000 benchmark episode represents a $2,000 per-episode exposure before behavioral adjustment. A 500-episode/year hospital faces $1 million in annual repayment risk if spending tracks at benchmark with no quality uplift. Achieving a Good CQS drops that to $1,000/episode ($500K annual exposure); Excellent eliminates the discount entirely. The ROI on care coordination infrastructure — care managers, SNF partnerships, post-discharge home visit programs — should be benchmarked against this per-episode savings opportunity. Recent reporting from Becker's ASC (November 2026) underscores that discharge process improvement is emerging as the primary operational lever hospitals are pulling first, consistent with this financial logic.
Cash flow risk is real. Reconciliation occurs approximately 6 months after the performance year ends. For PY1 (CY2028), hospitals won't see reconciliation payments or repayment obligations until mid-2029. Hospitals carry 12+ months of episode spending risk before financial settlement, with no interim payments. CFOs should build 2028 budgets assuming no reconciliation upside and reserving against potential repayment.
Post-episode spending trap: CMS subtracts spending in the 30 days following episode close (day 91-121) if average post-episode spending exceeds 3 standard deviations above the regional mean. This provision targets hospitals that discharge patients appropriately during the 90-day window but then see readmissions spike immediately after. Hospitals with high 30-day post-discharge readmission rates need to extend their coordination protocols past day 90, not just through it.
ACO-affiliated health systems are structurally advantaged. CJR-X episode spending counts within ACO expenditures (for MSSP attribution), but CJR-X reconciliation payments and repayments are financially separate — the models don't net against each other. An ACO-affiliated hospital that reduces LEJR episode spending can capture savings through both the CJR-X reconciliation payment and improved ACO shared savings performance. This double-capture opportunity is significant and should be explicitly modeled in any health system's VBC strategy.
Medicare Advantage plans are unaffected operationally — MA enrollees are excluded from CJR-X episodes entirely. But CJR-X's mandatory reach creates a natural experiment: hospitals investing in LEJR care coordination for Original Medicare will build infrastructure that MA plans can leverage for contract renegotiation. MA plans currently offering orthopedic bundled products should expect participating hospitals to come to the table with better cost data and care pathway capabilities by 2029.
High-volume orthopedic specialty hospitals (non-IPPS facilities) are exempt by definition. This creates a competitive asymmetry: ASC-based LEJR volume is entirely outside CJR-X (61% of hip procedures and 86% of knee procedures were performed in outpatient or ASC settings in 2024, per OACT). Hospitals losing LEJR volume to ASCs are losing CJR-X episode anchors — and therefore losing reconciliation payment opportunities — while also losing the fee-for-service revenue that funds care coordination infrastructure. This is the model's most underappreciated structural tension. Recent reporting from Becker's ASC (November 2026) indicates major health systems are explicitly developing strategies to manage this ASC volume dynamic under CJR-X.
Participant identification is now possible. The American Hospital Association reported in October 2026 that CMS has released the official list of CJR-X participants. This is a material competitive intelligence development: hospitals can now identify which competitors are subject to the model, benchmark their own LEJR volume and market position against named participants, and begin targeted partnership or network discussions with specific post-acute providers who serve shared patient populations. Health systems have not previously had this level of mandatory-model transparency at launch; the participant list should be integrated into any competitive analysis immediately.
TEAM participants (mandatory and voluntary) are excluded from CJR-X until TEAM concludes (2026-2030). When TEAM ends, eligible former TEAM hospitals automatically enter CJR-X. These hospitals will arrive with 4+ years of bundled payment infrastructure, making them structurally better positioned than CJR-X-naive competitors from day one.
Safety net hospitals face compounded pressure. Despite the 5% stop-loss and enhanced risk adjustment, high-dual hospitals often lack the ambulatory infrastructure to execute 90-day care coordination effectively. The SNF 3-day rule waiver (available under CJR-X) is a tool, but only for SNFs with ≥3 CMS stars for 7 of the past 12 months — a qualifying threshold that may exclude preferred SNF partners in underserved markets.
Hospitals bear the direct financial accountability. The mandatory structure eliminates the adverse selection problem that plagued BPCI Advanced (high-spending hospitals opted in; low-spending hospitals opted out), which is precisely why OACT certified savings. But that same mandatory structure means hospitals with limited post-acute network leverage — typically rural and community hospitals — carry repayment risk they cannot easily hedge. Immediate action items: (1) identify CJR-X collaborators and begin financial arrangement structuring under the Anti-Kickback Safe Harbor; (2) establish the beneficiary notification protocol; (3) submit the Primary Point of Contact Identification Form now.
Recent implementation evidence (October–November 2026) confirms that well-resourced hospitals are already in active preparation mode. The Techy Surgeon newsletter (October 2026) reports that hospitals are standing up dedicated CJR-X task forces, and vendor Navvis announced a purpose-built CJR-X operating capability solution in October 2026. Premier's November 2026 guidance to hospital leaders and Forvis Mazars' concurrent publication on population health strategy both indicate the advisory ecosystem has fully mobilized. The practical implication: hospitals that have not yet convened internal task forces are now observably behind peer institutions, not merely at risk of falling behind. The 14-month window to January 1, 2028 is the operative planning horizon, and 2027 infrastructure decisions will determine first-year performance outcomes.
Physicians face gainsharing dynamics that require careful structuring. The three-tier financial arrangement cascade (hospital → collaborator → collaboration agent → downstream collaboration agent) allows individual physicians to receive downstream distribution payments. Orthopedic surgeons — the primary drivers of post-acute utilization decisions — must be inside this arrangement or CJR-X will fail operationally. Hospitals that did not build robust gainsharing arrangements under CJR have 14 months to fix this before 2028.
Health system CFOs/CMOs should recognize that the PRO-PM measure (CMIT ID #1618) carries 10% of the composite quality score and applies to both inpatient and outpatient episodes. This is not a CJR carryover — CJR PRO reporting was voluntary. Mandatory PRO collection requires patient engagement infrastructure (apps, outreach workflows, data submission pipelines) that takes 12-18 months to operationalize. Systems that delay PRO infrastructure investment until 2027 will be starting their first performance year with incomplete quality data, risking a Below Acceptable CQS designation and total loss of reconciliation payment eligibility.
Payers and MA plans should treat CJR-X as a forced capability-building program for their hospital network partners. By 2029, CJR-X participants will have 12+ months of episode cost transparency, post-acute network performance data, and care transition protocols that MA plans can directly incorporate into value-based contracting. Plans that proactively align their orthopedic bundled products with CJR-X episode definitions — same MS-DRGs, same 90-day window — will reduce administrative friction for hospital partners and accelerate joint contracting.
Bottom line: CJR-X is finalized, participant lists are public, and the advisory and vendor ecosystem has fully mobilized as of late 2026. The model is structurally sound and actuarially certified to produce savings even without behavioral change. The model's greatest risk is not financial — it's operational readiness. With 14 months remaining before January 1, 2028, hospitals without active task forces are now measurably behind their peers. Prioritize PRO infrastructure, physician gainsharing restructuring, and post-acute network controls — in that order.